When an infected patient suffers from thrombocytosis, it is very difficult to identify beta-lactam antibiotic induced cases of the disease and separate these from the possibility that the disease is an acute-phase reaction in the infected patient. We present the case of a 54-year-old man who was treated with ceftazidime for pneumonia and developed thrombocytosis during the treatment course. Thrombocytosis persisted until ceftazidime was discontinued, despite clinical and radiological evidence showing that the pneumonia had greatly improved. The Naranjo probability scale indicates ceftazidime as the possible cause of the thrombocytosis in our patient. Although no obvious complications occur in most patients, we should pay close attention to the possibility of adverse reactions and evaluate whether the infection is treated with the appropriate antibiotics.
Aydogan T, Kanbay M, Alici O, et al. Incidence and etiology of thrombocytosis in an adult Turkish population. Platelets 2006;17:328–31.PubMedCrossRefGoogle Scholar
Parry MF, Jacobs B, Scully B, et al. Thrombocytosis: an acute-phase reactant, not an adverse reaction to the new beta-lactam antibiotics. Diagn Microbiol Infect Dis 1984;2:229–31.PubMedCrossRefGoogle Scholar
Buss DH, Stuart JJ, Lipscomb GE. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. Am J Hematol 1985;20:365–72.PubMedCrossRefGoogle Scholar
Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275–90.PubMedCrossRefGoogle Scholar
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45.PubMedCrossRefGoogle Scholar
Saathoff AD, Elkins SL, Chapman SW, et al. Thrombocytosis during antifungal therapy of candidemia. Ann Pharmacother 2005;39:1238–43.PubMedCrossRefGoogle Scholar